Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Authors: Alexa B. Kimball, Gregor B. E. Jemec, Christopher J. Sayed, Joslyn S. Kirby, Errol P. Prens, John R Ingram, Amit Garg, Alice B. Gottlieb, Jacek C. Szepietowski, Falk G. Bechara, Evangelos J. Giamarellos‐Bourboulis, Hideki Fujita, Robert Rolleri, Paulatsya Joshi, Pratiksha Dokhe, Edward Muller, Luke F. Peterson, Cynthia Madden, Muhammad Bari, Christos C. Zouboulis - The Lancet 2024 cited by 164